Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 19, 2022

Autologous Transplant vs CAR T-Cell Therapy for Relapsed DLBCL in Partial Remission

Blood

 

Additional Info

Blood
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Blood 2022 Mar 03;139(9)1330-1339, M Shadman, M Pasquini, KW Ahn, Y Chen, CJ Turtle, P Hematti, JB Cohen, F Khimani, S Ganguly, RW Merryman, JA Yared, FL Locke, N Ahmed, PN Munshi, A Beitinjaneh, PM Reagan, AF Herrera, CS Sauter, MA Kharfan-Dabaja, M Hamadani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading